BRIEF—ICER plans review of Vascepa and Xarelto

The USA’s Institute for Clinical and Economic Review (ICER)) on Friday announced that it plans to assess the comparative clinical effectiveness and value of additive cardiovascular disease (CVD) therapies Vascepa (icosapent ethyl), from Amarin Pharma, and Xarelto (rivaroxaban, marketed by Janssen Pharmaceuticals under a partnership with Germany’s Bayer.

The report will be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council in September of 2019.

The ICER’s website provides timelines of key posting dates and public comment periods for the assessment of additive CVD therapies.

An Open Input period began Friday and is intended to allow stakeholders to share key information relevant to the development of the evidence report.

Comments will be accepted from all interested stakeholders until March 12, 2019 at 5pm ET.

During this time, ICER will also contact key patient groups and clinical experts to gain further insights on the patient perspective and clinical context of treating CVD.